Brussels, Belgium, Belgium · Est. 1923 · 8,000 employees
UCB is a biopharmaceutical company focused on discovering and developing innovative medicines in immunology and neurology.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 6 drugs with upcoming expirations
Pipeline
By Phase
19 drugs in development
By Therapeutic Area
top 6
R&D Momentum
64/100
Pipeline Velocity
36/100
Trial Completion Rate
88/100
Pipeline Concentration
16/100
Pipeline Freshness
73/100
Strategic Signals
Activity
Last 14 days
A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2)
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Details
Company Overview
$20.0B
Mkt Cap
$5.3B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
Keppra — KEPPRA
Application NDA021505 (NDA)
Keppra — KEPPRA
Application NDA021872 (NDA)
Keppra — KEPPRA
Application NDA021035 (NDA)
Vimpat — VIMPAT
Application NDA022253 (NDA)
Vimpat — VIMPAT
Application NDA022254 (NDA)
Keppra — KEPPRA XR
Application NDA022285 (NDA)
Cimzia — CIMZIA
Application BLA125160 (BLA)
Vimpat — VIMPAT
Application NDA022255 (NDA)
Keppra — LEVETIRACETAM IN SODIUM CHLORIDE
Application NDA202543 (NDA)
Neupro — NEUPRO
Application NDA021829 (NDA)
Keppra — SPRITAM
Application NDA207958 (NDA)
Briviact — BRIVIACT
Application NDA205836 (NDA)
Briviact — BRIVIACT
Application NDA205838 (NDA)
Briviact — BRIVIACT
Application NDA205837 (NDA)
Keppra — ELEPSIA XR
Application NDA204417 (NDA)
Fintepla — FINTEPLA
Application NDA212102 (NDA)
Zilbrysq — ZILBRYSQ
Application NDA216834 (NDA)
Bimzelx — BIMZELX
Application BLA761151 (BLA)
Rysodeg — RYSTIGGO
Application BLA761286 (BLA)
Vimpat — MOTPOLY XR
Application NDA216185 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)